| General Information of Drug Metabolite (DM) (ID: DM019157) |
| DM Name |
MLN4924 Metabolite M3
|
| Structure |
|
|
3D MOL is unavailable
|
2D MOL is unavailable
|
|
|
|
|
|
|
|
| Full List of Drug-Metabolizing Enzyme (DME) Related to This DM |
| DME(s) Producing This DM through Metabolism |
| DME Name |
DME ID |
Reactant |
Reaction |
Related Drug |
REF |
|
Cytochrome P450 1A1 (CYP1A1)
|
DME0006
|
| Oxidation - Hydroxylation |
MLN4924
|
[1] |
|
Cytochrome P450 2J2 (CYP2J2)
|
DME0031
|
| Oxidation - Hydroxylation |
MLN4924
|
[1] |
|
Cytochrome P450 3A4 (CYP3A4)
|
DME0001
|
| Oxidation - Hydroxylation |
MLN4924
|
[1] |
|
Cytochrome P450 3A5 (CYP3A5)
|
DME0012
|
| Oxidation - Hydroxylation |
MLN4924
|
[1] |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Full List of Drug(s) That Produce This DM By Metabolism |
| MLN4924 |
DR3424
|
Phase 3 |
Myelodysplastic syndrome |
|
|
| References |
| 1 |
Metabolism and Disposition of [(14)C]Pevonedistat, a First-in-Class NEDD8-Activating Enzyme Inhibitor, after Intravenous Infusion to Patients with Advanced Solid Tumors
|
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.
